EQUILLIUM, INC. Other Comprehensive Income (Loss), Net of Tax
EQUILLIUM, INC. (EQ) reported Other Comprehensive Income (Loss), Net of Tax of $11.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $11.00K.
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was $7.00K.
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $93.00K, a 88.14% decline year-over-year.
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$115.00K.
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for fiscal 2025 was -$418.00K, a 165.21% decline from fiscal 2024.
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for fiscal 2024 was $641.00K, a 901.56% increase from fiscal 2023.
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $64.00K, a 70.09% decline from fiscal 2022.
- EQUILLIUM, INC. other comprehensive income (loss), net of tax for fiscal 2022 was $214.00K, a 34.59% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00K 10-Q · filed 2026-08-13 | $18.00K 10-Q · filed 2026-08-13 | $111.00K derived: sum of 3 quarters · filed 2026-08-13 | -$4.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $7.00K 10-Q · filed 2026-08-13 | $100.00K derived: sum of 2 quarters · filed 2026-08-13 | -$15.00K derived: sum of 3 quarters · filed 2026-08-13 | -$361.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$22.00K derived: sum of 2 quarters · filed 2026-03-25 | -$368.00K derived: sum of 3 quarters · filed 2026-08-13 | -$418.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | -$115.00K 10-Q · filed 2025-11-13 | -$461.00K derived: sum of 2 quarters · filed 2026-08-13 | -$511.00K 10-Q · filed 2025-11-13 | $273.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$346.00K 10-Q · filed 2026-08-13 | -$396.00K 10-Q · filed 2026-08-13 | $388.00K derived: sum of 3 quarters · filed 2026-08-13 | $134.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$50.00K 10-Q · filed 2026-08-13 | $734.00K derived: sum of 2 quarters · filed 2026-08-13 | $480.00K derived: sum of 3 quarters · filed 2026-08-13 | $308.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2024-12-31 | $784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $530.00K derived: sum of 2 quarters · filed 2026-03-25 | $358.00K derived: sum of 3 quarters · filed 2026-03-25 | $641.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | -$254.00K 10-Q · filed 2025-11-13 | -$426.00K derived: sum of 2 quarters · filed 2025-11-13 | -$143.00K 10-Q · filed 2025-11-13 | -$461.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$172.00K 10-Q · filed 2025-11-13 | $111.00K 10-Q · filed 2025-08-14 | -$207.00K derived: sum of 3 quarters · filed 2025-11-13 | -$89.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | $283.00K 10-Q · filed 2025-11-13 | -$35.00K derived: sum of 2 quarters · filed 2025-11-13 | $83.00K derived: sum of 3 quarters · filed 2025-11-13 | $118.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | -$318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$200.00K derived: sum of 2 quarters · filed 2025-03-27 | -$165.00K derived: sum of 3 quarters · filed 2025-03-27 | $64.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $118.00K 10-Q · filed 2024-11-13 | $153.00K derived: sum of 2 quarters · filed 2024-11-13 | $382.00K 10-Q · filed 2024-11-13 | $265.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $35.00K 10-Q · filed 2024-11-13 | $264.00K 10-Q · filed 2024-08-08 | $147.00K derived: sum of 3 quarters · filed 2024-11-13 | $489.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-03-31 | $229.00K 10-Q · filed 2024-11-13 | $112.00K derived: sum of 2 quarters · filed 2024-11-13 | $454.00K derived: sum of 3 quarters · filed 2024-11-13 | $759.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2022-12-31 | -$117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $225.00K derived: sum of 2 quarters · filed 2024-03-25 | $530.00K derived: sum of 3 quarters · filed 2024-03-25 | $214.00K 10-K · filed 2024-03-25 |
| 2022-09-30 | $342.00K 10-Q · filed 2023-11-08 | $647.00K derived: sum of 2 quarters · filed 2023-11-08 | $331.00K 10-Q · filed 2023-11-08 | $259.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $305.00K 10-Q · filed 2023-11-08 | -$11.00K 10-Q · filed 2023-08-09 | -$83.00K derived: sum of 3 quarters · filed 2023-11-08 | $60.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-03-31 | -$316.00K 10-Q · filed 2023-11-08 | -$388.00K derived: sum of 2 quarters · filed 2023-11-08 | -$245.00K derived: sum of 3 quarters · filed 2023-11-08 | -$199.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2021-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $71.00K derived: sum of 2 quarters · filed 2023-03-23 | $117.00K derived: sum of 3 quarters · filed 2023-03-23 | $159.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $143.00K 10-Q · filed 2022-11-14 | $189.00K derived: sum of 2 quarters · filed 2022-11-14 | $231.00K 10-Q · filed 2022-11-14 | -$37.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $46.00K 10-Q · filed 2022-11-14 | $88.00K 10-Q · filed 2022-08-15 | -$180.00K derived: sum of 3 quarters · filed 2022-11-14 | -$307.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | $42.00K 10-Q · filed 2022-11-14 | -$226.00K derived: sum of 2 quarters · filed 2022-11-14 | -$353.00K derived: sum of 3 quarters · filed 2022-11-14 | -$730.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2020-12-31 | -$268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$395.00K derived: sum of 2 quarters · filed 2022-03-23 | -$772.00K derived: sum of 3 quarters · filed 2022-03-23 | -$318.00K 10-K · filed 2022-03-23 |
| 2020-09-30 | -$127.00K 10-Q · filed 2021-11-10 | -$504.00K derived: sum of 2 quarters · filed 2021-11-10 | -$50.00K 10-Q · filed 2021-11-10 | -$110.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$377.00K 10-Q · filed 2021-11-10 | $76.00K 10-Q · filed 2021-08-10 | $17.00K derived: sum of 3 quarters · filed 2021-11-10 | $10.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-03-31 | $453.00K 10-Q · filed 2021-11-10 | $394.00K derived: sum of 2 quarters · filed 2021-11-10 | $387.00K derived: sum of 3 quarters · filed 2021-11-10 | $425.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2019-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | -$66.00K derived: sum of 2 quarters · filed 2021-03-24 | -$28.00K derived: sum of 3 quarters · filed 2021-03-24 | $16.00K 10-K · filed 2021-03-24 |
| 2019-09-30 | -$7.00K 10-Q · filed 2020-11-10 | $31.00K derived: sum of 2 quarters · filed 2020-11-10 | $75.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $38.00K 10-Q · filed 2020-11-10 | $82.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $44.00K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $5.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |